Investment: Medeva faces another tough year
Thursday 11 February 1999
The company said that a collapse in sales of Methylphenidate, its best selling treatment for hyperactive children, contributed to a 47 per cent plunge in pre-tax profits to pounds 59.3m in the first half of the financial year. Revenues from the drug have been savaged by the entry of a new competitor, Schein Pharmaceuticals, in the tightly regulated US market.
The near 40 per cent fall in Methylphenidate's revenue was only partially offset by an 11 per cent rise in the rest of Medeva's portfolio. The figures sent the shares down 2p to 102.5p, well below their 330p peak reached in 1997.
The finance director, Garry Watts, said profits would fall again this year, hit by the continuing slide in Methylphenidate's sales. However, he added that profits would recover in 2000 as new products entered the market.
Industry analysts are not so sure. Medeva's biggest hope to counter Methylphenidate's terminal decline is Hepagene, a vaccine for hepatitis B to be launched in the middle of 2000. Sales could reach some pounds 200m a year, not a spectacular level but enough to fuel Medeva's profits for some time.
However, Hepagene could become a real moneyspinner if Medeva can get it approved as a treatment of hepatitis as well as a vaccine. A positive result from clinical trials could push Hepagene's earnings potential to some pounds 500m overnight.
Medeva's problem is that the rest of the pipeline, which includes asthma and cough treatments and cancer drugs, is not exciting. The chief executive, Bill Bogie, maintains that its strategy of picking up fledgling drugs from biotechnology companies and old treatments from big pharmaceuticals groups while spending little on its own research will yield benefits in the long run.
One City analyst disagreed: "This strategy is unproven. This company needs a big product to drive growth."
After the recent slide, the shares are on just nine times 1999 earnings, expected to be around pounds 54m. But unless a predator comes in with a takeover, it's difficult to see how they will go up before 2000. As one analyst put it: "This is a growth stock without growth."
- 1 18th century sex toy found in 'toilet of sword fighting school' in Poland
- 2 US? China? India? The 10 biggest economies in 2030 will be...
- 3 'I wish my teacher knew...': Young students share their 'heartbreaking' worries in notes
General Election 2015: David Cameron catching up in polls – but he badly needs a clear lead
South Africa xenophobic attacks: Shops looted and violence on streets of Johannesburg as foreigners are forced to hide in police stations
18th century sex toy found in 'toilet of sword fighting school' in Poland
'I wish my teacher knew...': Young students share their 'heartbreaking' worries in notes
Rebecca Francis accuses Ricky Gervais of using 'influence' to target female hunters after receiving barrage of death threats
The only black face in the Ukip manifesto is on the page about overseas aid
If I’m being racially abused I don’t need a stranger with a saviour complex to rescue me
Ukip is the only main political party to not address LGBT rights in its manifesto
Food banks: One million Britons will soon be using them, according to Trussell Trust
BBC election debate: The one photo that summed up the whole 90-minute leaders debate
Religion isn't growing, it is becoming vigorous in its demise, says philosopher AC Grayling
iJobs Money & Business
£20000 - £25000 per annum + OTE £45,000: SThree: SThree Group have been well e...
£50000 - £667000 per annum + excellent benefits : Ashdown Group: IT Manager / ...
£13000 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...
£40000 - £45000 per annum + benefits : Ashdown Group: Training Programme Manag...